Compare Iris Energy Limited (IREN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

IREN trades at $38.69, down 6.27% today, amid a bearish technical trend and recent earnings misses. The company is aggressively pivoting from Bitcoin mining to AI infrastructure, securing multi-billion dollar contracts, but faces ballooning losses with a net income margin of -99.38% in 2026. Analyst consensus remains strongly bullish with a $81 price target, highlighting long-term revenue potential from AI demand, yet near-term execution and profitability challenges weigh on investor sentiment.

Outlook hinges on successful execution of AI expansion and cost management; opportunities include massive contracted revenue growth, but risks involve high capital burn, intense competition, and persistent negative earnings. The stock offers significant upside if targets are met, but volatility is expected amid transformative shifts.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.